Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK3 | P07288 | 8/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852996 | 0.85 | KLK3 (0.44) | KLK3F2PIK3CA | |
| SCHEMBL1862123 | 0.84 | HTT (0.53) | KLK3 | |
| SCHEMBL1855101 | 0.84 | KLK3 (0.67) | KLK3F2PIK3CAMKNK1MKNK2 | |
| SCHEMBL1852959 | 0.80 | TSHR (0.50) | KLK3 | |
| SCHEMBL1857455 | 0.80 | GPR119 (0.45) | KLK3F2PIK3CAGPR119MKNK1 | |
| SCHEMBL23910450 | 0.79 | KLK3 (0.41) | KLK3GPR119 | |
| SCHEMBL1855123 | 0.79 | KLK3 (0.44) | KLK3PIK3CAMKNK1MKNK2KCNH2 | |
| SCHEMBL1857851 | 0.78 | PIK3CA (0.42) | KLK3F2PIK3CAMKNK2PIK3CD | |
| SCHEMBL25409385 | 0.76 | KLK3 (0.57) | KLK3F2PIK3CAMKNK1MKNK2 | |
| SCHEMBL1855868 | 0.75 | POLB (0.43) | KLK3F2PIK3CAPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | KLK3 3112/4885F2 4753/4885PIK3CA 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.